Virax Biolabs Group Ltd, commonly known as VRAX, is a prominent global biotechnology company. Its headquarters are located in the United States, but its operations span across the globe, serving various industries ranging from medical to environmental.
Virax Biolabs Group Ltd, since its inception, has been dedicated to discovering, developing, producing, and marketing a wide array of innovative and efficient biomolecular solutions. It has earned a notable reputation for its ground-breaking work in the field of biotechnology, which is rooted in its robust research and development department composed of leading researchers and scientists.
VRAX's proficiency in the field lies in its biotechnological research, which includes the development of medical treatments and vaccinations, plant and animal genetics, and environmental solutions. The company has made significant strides in both infectious disease treatments and genetic research, leading to several patented innovations that have revolutionized the industry.
The firm operates under strict compliance with international standards and regulations. It continually puts tremendous investment in its infrastructure and technology, making sure it always stays ahead of the curve. The company operates with advanced biotechnological machinery and has high-tech laboratories facilitated with cutting-edge technology. This has enabled VRAX to provide commercial and custom services that are acknowledged and trusted worldwide.
VRAX is committed to adhere to ethical considerations in all its endeavors, focusing on leaving a positive impact on the community and the world. This is explicitly evident in their mission to create environmentally friendly bio-solutions to tackle the problem of waste management and climate change. The company's investments into creating biofuels and other renewable energy sources confirm their commitment to sustainable practices.
The strong leadership of Virax Biolabs Group Ltd, combined with their expert and highly motivated team, has made the company a driving force in the biotechnology industry. By building strategic partnerships and establishing strong relationships with their customers, VRAX has managed to leave a positive and significant impact in the field of biotechnology, promising a bright future ahead.
Virax Biolabs Group Ltd continues to grow as it leverages its exceptional capabilities to explore new frontiers in biotechnology. With its innovative solutions, VRAX is not just setting new benchmarks in the industry but also contributing significantly to improving the quality of life and enhancing environmental sustainability.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Virax Biolabs Group Ltd. has expanded its at-the-market (ATM) equity program by filing a sticker prospectus supplement with the SEC, increasing the maximum aggregate amount of ordinary shares that can be issued to $2,070,060.20. This move enhances the company's financial flexibility to raise equity capital and fund operations, although it may lead to dilution for existing shareholders. An analyst currently rates VRAX as a Buy with a $1.00 price target.
Virax Biolabs Group Ltd. (VRAX) has increased its at-the-market (ATM) share offering capacity to $2.07 million, adding to $3.66 million in ordinary shares already sold. This expansion provides Virax Biolabs with greater financial flexibility for equity funding but may lead to dilution for current shareholders. The company's stock currently has a Buy rating from one analyst with a $1.00 price target.
Virax Biolabs Group Ltd. (VRAX) raised approximately $3.3 million by allowing an investor to exercise preferred investment options for 548,000 shares at a reduced price of $6.00 per share. In exchange for this immediate cash infusion and price reduction, the company will issue new Series A and B preferred investment options covering 1.64 million shares, contingent on a shareholder-approved increase in authorized share capital. This move aims to strengthen near-term liquidity but introduces potential future equity dilution.
Virax Biolabs' UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect products, granting access to six Southeast Asian markets. This deal allows for immediate purchase-order-driven sales and phased expansion, with an initial focus on tuberculosis-related research in Thailand. The agreement is a significant commercial milestone for ImmuneSelect, distinct from the company's ViraxImmune diagnostic platform.
Virax Biolabs Group Limited (VRAX) stock surged 234.6% after announcing an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. The deal is expected to create immediate revenue potential in six Southeast Asian markets. The rally's magnitude may also be influenced by the stock's recent 1-for-25 share consolidation, which can increase volatility in small-cap companies.
Virax Biolabs Group Ltd. (VRAX) has approved a 1-for-25 share consolidation to be effective on June 26, 2026. This move, previously approved by shareholders, aims to raise the company's share price to meet Nasdaq's minimum $1 bid-price requirement and prevent delisting. The consolidation will not materially alter individual ownership percentages, aside from minor fractional share adjustments.
Virax Biolabs Group Ltd. (VRAX) has approved a 1-for-25 share consolidation, effective June 26, 2026, after shareholder approval. This move aims to increase the company's stock price to meet Nasdaq's minimum $1 bid price requirement and maintain its listing on the Nasdaq Capital Market. The consolidation will uniformly affect all shareholders, with minor adjustments for fractional shares, and will not materially change individual ownership percentages.